

PIENTER-onderzoek

No registrations found.

Ethical review	Positive opinion
Status	Pending
Health condition type	-
Study type	Observational non invasive

Summary

ID

NL-OMON24544

Source

NTR

Brief title

PIENTER3

Health condition

The age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population

Sponsors and support

Primary sponsor: National Institute for Public Health and the Environment (RIVM)

Source(s) of monetary or material Support: Ministry of Health, Welfare and Sports (VWS)

Intervention

Outcome measures

Primary outcome

The age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population.

Secondary outcome

The age-specific seroprevalence against other infectious diseases, in particular those that might be vaccine-preventable in the near future and against those diseases with a frequent subclinical course.

By collecting additional samples, the relationship between immune status and carriage of potential pathogens, lifestyle factors and environmental factors can be studied.

Study description

Background summary

Measuring the serological effects of the different vaccinations (immune surveillance) is an important tool for the evaluation of the National Immunisation Programme (NIP) by providing insight in the immune status of the population, by identifying possible gaps in the immunity and subpopulations at risk and by assessing (re) emergence of disease. To obtain insight into the age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population, this observational study with a single invasive measurement (drawing of blood) and non-invasive measurement (saliva) is performed. For a subgroup, optional, a nose and throat swab will be collected as well as a faecal sample. A representative part sample of the Dutch population (age 0-89 years) is invited to participate. The age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population and against other infectious diseases, in particular those that might be vaccine-preventable in the near future and against those diseases with a frequent subclinical course, will be assessed.

Study objective

Rationale: Measuring the serological effects of the different vaccinations (immune surveillance) is an important tool for the evaluation of the National Immunisation Programme (NIP) by providing insight in the immune status of the population, by identifying possible gaps in the immunity and subpopulations at risk and by assessing (re) emergence of disease.

Study design

A single time point for the collection of samples.

Intervention

None

Contacts

Public

Antonie van Leeuwenhoeklaan 9-11
R.A.J. Boxtel, van
Bilthoven 3721 MA
The Netherlands
+31 (0)30 2742755

Scientific

Antonie van Leeuwenhoeklaan 9-11
R.A.J. Boxtel, van
Bilthoven 3721 MA
The Netherlands
+31 (0)30 2742755

Eligibility criteria

Inclusion criteria

- Subject is part of the national study sample drawn from the population register, aged 0 to 89 year old and has received a personal invitation for the PIENTER study.
- Subject has given written Informed Consent (IC) before the start of the study visit.

Exclusion criteria

None

Study design

Design

Study type: Observational non invasive
Intervention model: Other

Control: N/A , unknown

Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-02-2016
Enrollment:	8400
Type:	Anticipated

Ethics review

Positive opinion	
Date:	05-01-2016
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL5467
NTR-old	NTR5611
Other	NL54228.094.15 : IIV-284

Study results

Summary results

Van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA. Second national serum

bank for population-based seroprevalence studies in the Netherlands. Neth J Med. 2009 Jul-Aug;67(7):301-8.

Mollema L, de Melker HE, Hahné SJM, van Weert JWM, Berbers GAM, van der Klis FRM.

PIENTER 2 project: second research project on the protection against infectious diseases offered by the national immunization programme in the Netherlands. RIVM report 230421001/2009.

PIENTER2 study 2006-2007: A summary of the main findings. Van der Klis FRM, Mollema L, van Weert JWM. RIVM report, April 2012.